Symbols / EDSA Stock $7.06 +4.13% Edesa Biotech, Inc.
EDSA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Ratings
Current target
$7.06
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
- $EDSA stock is down 8% today. Here's what we see in our data. | EDSA Stock News - Quiver Quantitative Wed, 22 Apr 2026 14
- Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying - Yahoo Finance hu, 23 Apr 2026 10
- Edesa (EDSA) Stock Insider Buying (Breakout Watch) 2026-04-20 - Trend Signals - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 18
- Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits ue, 24 Feb 2026 20
- A Phase 3 ARDS treatment study gets the opening talk at an ATS summit - Stock Titan ue, 31 Mar 2026 07
- EDSA Edesa Biotech Inc. Common Shares posts narrower Q1 2026 loss than consensus forecasts, shares gain on upbeat investor sentiment. - Cost Structure - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 01
- Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com ue, 24 Feb 2026 08
- $EDSA stock is up 28% today. Here's what we see in our data. | EDSA Stock News - Quiver Quantitative ue, 03 Mar 2026 08
- Edesa drug cuts death risk to 24% in Phase 3 ARDS trial - Stock Titan ue, 24 Feb 2026 08
- Edesa Biotech (EDSA) CEO receives 2,578-share restricted stock grant - Stock Titan Fri, 10 Apr 2026 07
- Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan Mon, 02 Mar 2026 08
- Insider Purchase: Chief Executive Officer of $EDSA Buys 10,000 Shares | EDSA Stock News - Quiver Quantitative Wed, 04 Mar 2026 08
- Edesa Biotech (EDSA) CEO adds 1,000 shares in open-market buy - Stock Titan ue, 10 Mar 2026 07
- Edesa Biotech, Inc. Reports Q1 2026 Financial Results and Updates on Clinical Programs for EB06 and Paridiprubart - Quiver Quantitative Fri, 13 Feb 2026 08
- Edesa Biotech readies vitiligo trial after ARDS drug's Phase 3 success - Stock Titan Fri, 13 Feb 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Gross Profit |
|
—
|
—
|
—
|
—
|
| Operating Expense |
|
7.13
+12.84%
|
6.32
-26.91%
|
8.64
-50.87%
|
17.59
|
| Research And Development |
|
3.67
+27.30%
|
2.88
-39.89%
|
4.79
-64.05%
|
13.34
|
| Selling General And Administration |
|
4.24
+2.66%
|
4.13
-6.67%
|
4.43
-12.06%
|
5.04
|
| General And Administrative Expense |
|
4.24
+2.66%
|
4.13
-6.67%
|
4.43
-12.06%
|
5.04
|
| Other Gand A |
|
4.24
+2.66%
|
4.13
-6.67%
|
4.43
-12.06%
|
5.04
|
| Other Operating Expenses |
|
-0.78
-12.26%
|
-0.70
-20.18%
|
-0.58
+25.53%
|
-0.78
|
| Total Expenses |
|
7.13
+12.84%
|
6.32
-26.91%
|
8.64
-50.87%
|
17.59
|
| Operating Income |
|
-7.13
-12.84%
|
-6.32
+26.91%
|
-8.64
+50.87%
|
-17.59
|
| Total Operating Income As Reported |
|
-7.91
-12.78%
|
-7.01
+23.94%
|
-9.22
+49.80%
|
-18.37
|
| EBITDA |
|
-7.01
-14.32%
|
-6.13
+27.52%
|
-8.46
+51.59%
|
-17.47
|
| Normalized EBITDA |
|
-6.95
-13.74%
|
-6.11
+27.58%
|
-8.44
+51.66%
|
-17.45
|
| Reconciled Depreciation |
|
0.12
-35.89%
|
0.19
+1.41%
|
0.18
+55.24%
|
0.12
|
| EBIT |
|
-7.13
-12.84%
|
-6.32
+26.91%
|
-8.64
+50.87%
|
-17.59
|
| Total Unusual Items |
|
-0.06
-183.29%
|
-0.02
+3.22%
|
-0.02
-2.97%
|
-0.02
|
| Total Unusual Items Excluding Goodwill |
|
-0.06
-183.29%
|
-0.02
+3.22%
|
-0.02
-2.97%
|
-0.02
|
| Net Income |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Pretax Income |
|
-7.18
-16.46%
|
-6.17
+26.33%
|
-8.37
+52.28%
|
-17.55
|
| Net Non Operating Interest Income Expense |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Net Interest Income |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Interest Income Non Operating |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Interest Income |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Other Income Expense |
|
-0.06
-849.79%
|
-0.01
+71.13%
|
-0.02
-2.97%
|
-0.02
|
| Other Non Operating Income Expenses |
|
—
|
0.01
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.06
-183.29%
|
-0.02
+3.22%
|
-0.02
-2.97%
|
-0.02
|
| Tax Provision |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
-62.50%
|
0.00
+52.61%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.01
-183.29%
|
-0.00
+63.71%
|
-0.01
-57.15%
|
-0.01
|
| Net Income Including Noncontrolling Interests |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Net Income From Continuing And Discontinued Operation |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Net Income Continuous Operations |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Normalized Income |
|
-7.13
-15.97%
|
-6.15
+26.42%
|
-8.36
+52.31%
|
-17.53
|
| Net Income Common Stockholders |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Diluted EPS |
|
-1.27
+34.20%
|
-1.93
+34.13%
|
-2.93
+60.14%
|
-7.35
|
| Basic EPS |
|
-1.27
+34.20%
|
-1.93
+34.13%
|
-2.93
+60.14%
|
-7.35
|
| Basic Average Shares |
|
5.68
+77.54%
|
3.20
+11.84%
|
2.86
+20.11%
|
2.38
|
| Diluted Average Shares |
|
5.68
+77.54%
|
3.20
+11.84%
|
2.86
+20.11%
|
2.38
|
| Diluted NI Availto Com Stockholders |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
13.53
+254.76%
|
3.81
-57.10%
|
8.89
-23.20%
|
11.58
|
| Current Assets |
|
11.51
+587.08%
|
1.68
-73.97%
|
6.44
-29.20%
|
9.09
|
| Cash Cash Equivalents And Short Term Investments |
|
10.79
+940.39%
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
|
| Cash And Cash Equivalents |
|
10.79
+940.39%
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
|
| Receivables |
|
0.64
+137.30%
|
0.27
-56.76%
|
0.63
-50.09%
|
1.26
|
| Accounts Receivable |
|
0.64
+137.30%
|
0.27
-56.76%
|
0.63
-50.09%
|
1.26
|
| Prepaid Assets |
|
—
|
—
|
—
|
0.75
|
| Other Current Assets |
|
0.08
-78.81%
|
0.37
-18.16%
|
0.45
-39.79%
|
0.75
|
| Total Non Current Assets |
|
2.02
-5.65%
|
2.14
-12.85%
|
2.45
-1.22%
|
2.48
|
| Net PPE |
|
0.00
-100.00%
|
0.02
-81.65%
|
0.10
+221.18%
|
0.03
|
| Gross PPE |
|
0.00
-100.00%
|
0.02
-87.24%
|
0.14
+103.63%
|
0.07
|
| Accumulated Depreciation |
|
—
|
-0.05
-19.85%
|
-0.04
-10.95%
|
-0.04
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
0.02
|
| Machinery Furniture Equipment |
|
—
|
0.05
+0.00%
|
0.05
+0.64%
|
0.05
|
| Other Properties |
|
—
|
0.02
-79.91%
|
0.09
+394.84%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
1.98
-4.87%
|
2.08
-4.64%
|
2.18
-4.44%
|
2.28
|
| Other Intangible Assets |
|
1.98
-4.87%
|
2.08
-4.64%
|
2.18
-4.44%
|
2.28
|
| Non Current Prepaid Assets |
|
0.04
-2.88%
|
0.04
-76.28%
|
0.17
+1.18%
|
0.17
|
| Total Liabilities Net Minority Interest |
|
1.08
-41.15%
|
1.83
-0.48%
|
1.84
-15.69%
|
2.18
|
| Current Liabilities |
|
1.08
-41.15%
|
1.83
+0.60%
|
1.82
-14.90%
|
2.14
|
| Payables And Accrued Expenses |
|
1.08
-40.51%
|
1.81
+3.77%
|
1.75
-17.66%
|
2.12
|
| Current Debt And Capital Lease Obligation |
|
—
|
0.02
-73.41%
|
0.07
+293.75%
|
0.02
|
| Current Capital Lease Obligation |
|
0.00
-100.00%
|
0.02
-73.41%
|
0.07
+293.75%
|
0.02
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.02
-54.71%
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.02
|
0.00
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.02
|
0.00
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
12.45
+528.52%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Common Stock Equity |
|
3.19
+61.11%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Capital Stock |
|
63.78
+35.01%
|
47.24
+1.27%
|
46.64
+9.82%
|
42.47
|
| Common Stock |
|
54.52
+15.41%
|
47.24
+1.27%
|
46.64
+9.82%
|
42.47
|
| Preferred Stock |
|
9.26
|
0.00
|
—
|
—
|
| Share Issued |
|
7.14
+119.92%
|
3.25
+5.59%
|
3.08
+29.21%
|
2.38
|
| Ordinary Shares Number |
|
7.14
+119.92%
|
3.25
+5.59%
|
3.08
+29.21%
|
2.38
|
| Additional Paid In Capital |
|
14.75
+8.66%
|
13.58
+4.12%
|
13.04
+16.67%
|
11.18
|
| Retained Earnings |
|
-65.91
-12.50%
|
-58.59
-11.77%
|
-52.42
-19.01%
|
-44.04
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.17
+31.67%
|
-0.24
-13.03%
|
-0.21
-0.49%
|
-0.21
|
| Other Equity Adjustments |
|
-0.17
+31.67%
|
-0.24
-13.03%
|
-0.21
-0.49%
|
-0.21
|
| Total Equity Gross Minority Interest |
|
12.45
+528.52%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Total Capitalization |
|
12.45
+528.52%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Working Capital |
|
10.43
+6737.41%
|
-0.16
-103.41%
|
4.61
-33.61%
|
6.95
|
| Invested Capital |
|
3.19
+61.11%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Total Debt |
|
0.00
-100.00%
|
0.02
-78.97%
|
0.09
+397.96%
|
0.02
|
| Capital Lease Obligations |
|
0.00
-100.00%
|
0.02
-78.97%
|
0.09
+397.96%
|
0.02
|
| Net Tangible Assets |
|
10.47
+10821.65%
|
-0.10
-102.01%
|
4.87
-31.52%
|
7.11
|
| Tangible Book Value |
|
1.21
+1342.78%
|
-0.10
-102.01%
|
4.87
-31.52%
|
7.11
|
| Other Equity Interest |
|
—
|
—
|
—
|
-0.21
|
| Preferred Stock Equity |
|
9.26
|
—
|
—
|
—
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.32
-49.73%
|
-4.89
+26.31%
|
-6.64
+45.95%
|
-12.28
|
| Cash Flow From Continuing Operating Activities |
|
-7.32
-49.73%
|
-4.89
+26.31%
|
-6.64
+45.95%
|
-12.28
|
| Net Income From Continuing Operations |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Depreciation Amortization Depletion |
|
0.12
-35.89%
|
0.19
+1.41%
|
0.18
+55.24%
|
0.12
|
| Depreciation And Amortization |
|
0.12
-35.89%
|
0.19
+1.41%
|
0.18
+55.24%
|
0.12
|
| Other Non Cash Items |
|
—
|
-0.01
|
—
|
—
|
| Stock Based Compensation |
|
0.73
+35.75%
|
0.54
-56.88%
|
1.25
-44.86%
|
2.26
|
| Change In Working Capital |
|
-0.99
-272.60%
|
0.57
+85.41%
|
0.31
-89.35%
|
2.89
|
| Change In Receivables |
|
-0.38
-206.08%
|
0.36
-36.68%
|
0.56
-72.24%
|
2.03
|
| Change In Prepaid Assets |
|
0.11
-45.30%
|
0.20
-34.62%
|
0.30
+1646.41%
|
-0.02
|
| Change In Payables And Accrued Expense |
|
-0.72
-4167.65%
|
0.02
+103.16%
|
-0.56
-163.01%
|
0.88
|
| Investing Cash Flow |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Net PPE Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Purchase Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
17.03
+2776.69%
|
0.59
-87.74%
|
4.83
-58.47%
|
11.63
|
| Cash Flow From Continuing Financing Activities |
|
17.03
+2776.69%
|
0.59
-87.74%
|
4.83
-58.47%
|
11.63
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.03
|
0.00
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.03
|
0.00
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
-0.03
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
—
|
-0.03
|
0.00
|
—
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.03
|
—
|
—
|
| Net Short Term Debt Issuance |
|
0.00
+100.00%
|
-0.03
|
—
|
—
|
| Net Common Stock Issuance |
|
7.72
+958.10%
|
0.73
-83.21%
|
4.35
-63.66%
|
11.96
|
| Proceeds From Stock Option Exercised |
|
-0.02
|
0.00
-100.00%
|
0.77
|
0.00
|
| Net Other Financing Charges |
|
-0.54
-404.63%
|
-0.11
+62.23%
|
-0.29
+12.99%
|
-0.33
|
| Changes In Cash |
|
9.71
+325.88%
|
-4.30
-137.95%
|
-1.81
-175.64%
|
-0.66
|
| Effect Of Exchange Rate Changes |
|
0.05
+278.42%
|
-0.03
-133.71%
|
0.08
+182.63%
|
-0.09
|
| Beginning Cash Position |
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
-9.55%
|
7.84
|
| End Cash Position |
|
10.79
+940.39%
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
|
| Free Cash Flow |
|
-7.32
-49.73%
|
-4.89
+26.31%
|
-6.64
+45.98%
|
-12.28
|
| Common Stock Issuance |
|
7.72
+958.10%
|
0.73
-83.21%
|
4.35
-63.66%
|
11.96
|
| Issuance Of Capital Stock |
|
17.60
+2312.77%
|
0.73
-83.21%
|
4.35
-63.66%
|
11.96
|
| Net Preferred Stock Issuance |
|
9.88
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
9.88
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-10 View
- 42026-03-11 View
- 42026-03-10 View
- 42026-03-06 View
- 42026-03-05 View
- 42026-03-04 View
- 42026-03-03 View
- 42026-03-02 View
- 42026-03-02 View
- 8-K2026-02-24 View
- 10-Q2026-02-13 View
- 8-K2026-02-13 View
- 42026-02-02 View
- 42026-01-05 View
- 8-K2025-12-12 View
- 10-K2025-12-12 View
- 8-K2025-12-12 View
- 42025-12-02 View
- 42025-11-06 View
- 8-K2025-10-28 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|